بيرو - الإسبانية - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

glaxosmithkline peru s.a. - antigeno de superficie purificado de hepatitis b; antigeno del virus de la hepatitis a; - suspension inyectable - por jeringa prellenada1 ml; antigeno de superficie purificado de hepatitis b 20.000000 mcg; antigeno del virus de la hepatitis a 720.000000 u; - combinaciones

الاتحاد الأوروبي - الإسبانية - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vacunas - infanrix penta está indicado para la vacunación primaria y de refuerzo de los lactantes contra la difteria, el tétanos, la tos ferina, la hepatitis b y la poliomielitis..

الاتحاد الأوروبي - الإسبانية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals para felidae, - gatos - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

الاتحاد الأوروبي - الإسبانية - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals para felidae, - gatos - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. los inicios de inmunidad se han demostrado 1 semana después del ciclo de vacunación primaria para componentes de rinotraqueitis, calicivirus y chlamydophila felis.. la duración de la inmunidad es de 1 año después de la última (re) vacunación.

الاتحاد الأوروبي - الإسبانية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals para felidae, - gatos - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

الاتحاد الأوروبي - الإسبانية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals para felidae, - gatos - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. se han demostrado los inicios de inmunidad una semana después del ciclo de vacunación primaria para componentes de rinotraqueitis, calicivirus, chlamydophila felis y panleucopenia. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

الاتحاد الأوروبي - الإسبانية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals para felidae, - gatos - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

إسبانيا - الإسبانية - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zoetis spain, s.l. - antigeno capsular, leucotoxoide - polvo para soluciÓn inyectable - excipientes: cloruro potasico, anfigen, hidroxido de aluminio gel, sorbitan monooleato, tampon fosfato, hidrogenofosfato de sodio dihidrato, edta (etilendiamino tetraacetico), butil paraben, polisorbato 80, cloruro de sodio, fosfato potasico monobasico, tiomersal, drakeol 5, metilparabeno (e 218), propilparabeno (e 216) - vacunas bacterianas inactivadas (incluyendo micoplasma, clamidia y toxoide) - bovino

الأرجنتين - الإسبانية - SANI (Asociación de Cooperativas Argentinas)

boehringer ingelheim - circovirus porcino tipo 2 antígeno orf2 - circovirus porcino tipo 2 antígeno orf2 - prevención de la enfermedad asociada al circovirus porcino. - porcinos

الأرجنتين - الإسبانية - SANI (Asociación de Cooperativas Argentinas)

msd salud animal - circo virus porcino tipo 2 antígeno subunitario orf2 - circo virus porcino tipo 2 antígeno subunitario orf2 - circumvent®pcv es una vacuna subunitaria adyuvantada inactivada que contiene la proteína orf2 del circovirus porcino tipo 2 como ingrediente activo. la vacuna está adyuvantada con un adyuvante agua en aceite para estimular una respuesta inmune adecuada. - porcinos